Home Drug Discovery Antibodies Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR...

Houser_191216_6194 — Novo Nordisk has agreed to acquire the ATTR candidate PRX004 from Prothena for up to $1.2 billion. Novo was among companies that expressed to Prothena their interest in developing the humanized monoclonal antibody. [Novo Nordisk]

Heart of the Deal: Prothena Executives on the $1.2B Sale of ATTR Amyloidosis Candidate to Novo Nordisk

Buyer further builds cardiovascular pipeline with purchase of PRX004

By Alex Philippidis

July 21, 2021

Novo Nordisk has agreed to acquire the ATTR candidate PRX004 from Prothena for up to $1.2 billion. Novo was among companies that expressed to Prothena their interest in developing the humanized monoclonal antibody. [Novo Nordisk]

The deal, announced last week, gives Prothena $60 million in upfront cash and potentially up to $1.17 billion tied to achieving development, commercialization and net sales-based milestones, starting with $40 million if the anti-amyloid immunotherapy advances to Phase II . . .